drugset / Trial / NCT04892251

Ketamine Assisted Psychotherapy for Opioid Use Disorder

NCT04892251

Phase 1/2 Recruiting 60 enrolled University of Utah
RandomizedParallel-groupDouble-blindTreatment

Summary

This pilot clinical trial aims to assess the preliminary efficacy of ketamine as an adjunct for a mindfulness-based intervention for opioid use disorder.

Timeline

Start
2021-05-20
Primary completion
2023-12-30
Completion
2024-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intramuscular
Subject Ketamine Small molecule 1.5 mg/kg Intramuscular

Indications